Protocols
Research Stage
A 2025 PNAS study from Yale found that semaglutide recruits — rather than silences — AgRP hunger neurons in female mice, and that this recruitment is required for the drug's full weight-lowering effect. A parallel JCI study confirmed rapid AgRP inhibition at pharmacologic doses, revealing a context-dependent, bidirectional relationship between GLP-1 receptor agonists and hypothalamic hunger circuitry.
September 7, 2026
·
11 min read
Protocols
Research Stage
Neither BPC-157 nor TB-500 has completed a human randomised controlled trial for ulcerative colitis, wound healing, or pain as of 2026. FDA staff concluded the evidence was inadequate for all three indications. An advisory committee nonetheless voted 8-6 in favour of adding both to the 503A compounding list — a non-binding recommendation that has not yet changed legal compounding status.
September 3, 2026
·
11 min read
Protocols
Research Stage
As of 2026, the human dose-response record for BPC-157 consists of a Phase 1 tolerability study in two healthy adults, an unpublished Phase 2 enema trial in ulcerative colitis, and a small number of soft-tissue case series. No dose-response curve has been established in humans for any indication. FDA reviewers characterised the available data as sparse, short, and exploratory.
September 2, 2026
·
11 min read
Protocols
Research Stage
Administration route materially alters BPC-157's pharmacokinetic profile and, by extension, which tissue-injury types are most likely to respond. Two 2026 reviews — Mateescu in Pharmaceutics and Yuan in IJMS — establish that subcutaneous injection favours musculoskeletal targets, oral administration favours gastrointestinal mucosa, and intra-articular delivery is supported by a small human case series for joint pathology.
August 31, 2026
·
10 min read
Protocols
Research Stage
As of 2026, no completed randomised controlled trial has evaluated emideltide — the synthetic analogue of delta sleep-inducing peptide (DSIP) — in insomnia, narcolepsy, or opioid use disorder. The available human record consists of small uncontrolled Soviet-era infusion studies and one opioid withdrawal series. Regulators have explicitly cited this evidence gap as the central barrier to any compounding pathway.
August 20, 2026
·
11 min read
Protocols
Research Stage
No validated safe dose for BPC-157 in humans has been established as of 2026. The compound carries five categorised safety risk classes — oncological, immunogenic, cardiovascular, neurological, and drug-interaction — each grounded in preclinical mechanism rather than observed human adverse events. No completed human pharmacokinetic study exists, making rational dose selection impossible by current clinical standards.
August 17, 2026
·
12 min read